2025年2月18日 · Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform

Using a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer. Lead programs include both …

2022年4月1日 · When coexpressed with a natural killer group 2D (NKG2D) CAR, the allogeneic T cells (called CYAD-101) failed to induce graft-versus-host disease in mouse models while …

Background: CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) receptor, which binds eight ligands that are …

2019年11月13日 · By using a single vector encoding the NKG2D-based CAR next to a shRNA targeting MICA and MICB and combined with improved cell culture methods, CYAD-02, the …

2020年5月25日 · CYAD-101 is an allogeneic CAR-T that uses a non-gene edited peptide-based technology (TIM) to control graft versus host disease (GvHD) combined with a NKG2D-based …

CYAD-211 is the Company’s first allogeneic chimeric antigen receptor (CAR) T-cell candidate, engineered to co-express a B-cell maturation antigen (BCMA)-specific CAR and a microRNA …

2021年1月22日 · Background: CYAD-101 is a first-in-class, non-gene edited allogeneic CAR T-cell product that combines the broad breadth of tumor targeting of the NKG2D-based chimeric …

CYAD-101: 一种NKG2D拮抗剂药物，由Celyad Oncology SA (Celyad Oncology SA)公司最早进行研发，目前全球最高研发状态为临床1期，作用机制: NKG2D拮抗剂(杀伤细胞凝集素样受体K1 …

2021年11月5日 · CYAD-211 is an allogeneic anti-BCMA CAR T that co-expresses a shRNA targeting CD3z which results in reduction of cell surface TCR expression. IMMUNICY-1 is an …